Log in

Relevant bibliographies by topics / Theophylline / Journal articles

To see the other types of publications on this topic, follow the link: Theophylline.

Journal articles on the topic 'Theophylline'

Author: Grafiati

Published: 4 June 2021

Last updated: 29 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Theophylline.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Tatsis, G., J. Danos, M. Gaga, D. Pantelakis, M. Veslemes, and J. Jordanoglou. "A Single-Blind Crossover Study of Two Different Slow Release Theophylline Preparations." Journal of International Medical Research 16, no. 6 (November 1988): 452–58. http://dx.doi.org/10.1177/030006058801600607.

Full text

Abstract:

In a single-blind crossover study, two slow release theophylline preparations were evaluated in 18 patients with chronic bronchitis or asthma without cardiac, renal or liver disease. After randomization into two groups, patients were treated, in a crossover study design, with 600 mg choline theophyllinate or 300 mg anhydrous theophylline administered orally every 12 h for 7 days. A 2-day washout period separated the two periods of treatment evaluation. Blood samples in which plasma theophylline concentration was to be measured were taken at 7.30 a.m., 2.00 p.m. and 7.30 p.m. during the last 5 days of therapy with each drug. The mean fluctuation in plasma theophylline concentration was ≤40% in all 18 patients taking choline theophyllinate yet in only 15 (83%) patients administered anhydrous theophylline. Salbutamol inhaler was more frequently required for the relief of bronchospasm when taking anhydrous theophylline than when taking choline theophyllinate (total of 41 vs 25 puffs, respectively, over 7 days). Drug-related adverse reactions occurred in four patients while taking anhydrous theophylline and in one patient while taking choline theophyllinate.

APA, Harvard, Vancouver, ISO, and other styles

2

Ali, Tasneem Basheer, Huda Yousef Almomani, Fatima Mahmoud Al-Tarawneh, Maysa Waddah Alwadi, and Ahmad Shaher Suliman. "Physicians' Knowledge of Theophylline Use: A Cross-Sectional Study from Jordan." Jordan Journal of Pharmaceutical Sciences 16, no. 4 (December 25, 2023): 857–70. http://dx.doi.org/10.35516/jjps.v16i4.1789.

Full text

Abstract:

Objective: This cross-sectional study aims to assess physicians' knowledge regarding theophylline drug and other related characteristics in Jordan. Materials and Method: The study was conducted prospectively among physicians in Jordan. Physicians were interviewed using an online questionnaire consisting of two sections. The first section included demographics and other relevant characteristics, while the second section comprised questions about theophylline drug. Results: A total of 385 participants completed the questionnaire. The majority of participants knew that theophylline is used in clinical practice as a bronchodilator (75.6%). Nearly 39% of participants knew that theophylline can be administered orally and intravenously. The largest share of participants (76.1%) did not know that theophylline dosage is calculated based on ideal body weight. Sixty percent of participants knew that theophylline use was not contraindicated during pregnancy. On the other hand, only 27.3% knew that theophylline use was not contraindicated during breastfeeding. The majority of participants (76.1%) had an overall intermediate knowledge of theophylline. Conclusions: It was noted that physicians had an overall intermediate knowledge of theophylline. Physicians demonstrated unsatisfactory knowledge about theophylline’s indications, clinical use, administration, adverse effects, and other related aspects. These findings highlight the need for educational interventions and training programs to improve physicians’ knowledge of theophylline and enhance its effective and safe use in clinical practice.

APA, Harvard, Vancouver, ISO, and other styles

3

Malamatari, Maria. "Inhaled theophylline: old drug new tricks?" International Journal of Basic & Clinical Pharmacology 13, no. 1 (December 26, 2023): 174–80. http://dx.doi.org/10.18203/2319-2003.ijbcp20233912.

Full text

Abstract:

Theophylline and aminophylline (i.e., the soluble complex of theophylline with ethylenediamine) have been used in the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease for more than 90 years. Theophylline’s narrow therapeutic index and side effects, as well as the discovery of more potent and safer bronchodilators, made it to fall out of favour with healthcare professionals and patients. New scientific knowledge on the molecular mechanism of action of theophylline, along with increasing clinical evidence suggest that theophylline should be exploited as an anti-inflammatory agent rather than a bronchodilator. This review covers the journey of theophylline from rise to fall and back to its potential re-emergence as a combination formulation with inhaled corticosteroids in the management of chronic inflammatory lung diseases. Several approaches to formulate theophylline either as a monotherapy or as a combination therapy for delivery to the lungs are presented.

APA, Harvard, Vancouver, ISO, and other styles

4

Boner, A. L., G. De Stefano, G. Vallone, M. Plebani, and P. Ventura. "Absolute and Relative Bioavailability of a Slow Release Theophylline Preparation in Asthmatic Children." Journal of International Medical Research 15, no. 5 (September 1987): 282–92. http://dx.doi.org/10.1177/030006058701500504.

Full text

Abstract:

This study was carried out on 14 asthmatic childen aged 7–13 years. They all received three preparations (aminophylline by intravenous infusion, lysine theophyllinate orally in solution and slow release theophylline orally as capsules) in a single dose of 100 mg active ingredient in a crossover design. Plasma theophylline concentrations, determined by a fluorescent polarization immunoassay, were evaluated both by compartmental and non-compartmental analysis. After administration of slow release theophylline, its maximum plasma concentration and the time needed to reach this were (± SD) 3.19 ± 0.63 μg/ml and 8.71 ± 2.30 h, respectively, compared to 4.51 ± 0.94 μg/ml and 1.96 ± 0.85 h, respectively, for the oral normal release solution. Mean absolute and relative percentage bioavailabilities for slow release theophylline in asthmatic children were (± SD) 92.7 ± 23.2% and 83.14 ± 14.69%, respectively. These are similar to the values found with other slow release formulations in paediatric patients.

APA, Harvard, Vancouver, ISO, and other styles

5

BRODWALL, ERLING K. "The Resorption of Theophyllamine (Theophylline Ethylenediamine)." Acta Medica Scandinavica 146, no. 2 (April 24, 2009): 123–26. http://dx.doi.org/10.1111/j.0954-6820.1953.tb10222.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Nolte, Matthias, Ingo Pantenburg, and Gerd Meyer. "Konkurrierende Liganden: Theophyllin als nicht- und stark koordinierender Ligand in Quecksilber(II)-Komplexen / Competing Ligands: Theophylline as Non- and Strongly Coordinating Ligand in Mercury(II) Complexes." Zeitschrift für Naturforschung B 61, no. 6 (June 1, 2006): 758–65. http://dx.doi.org/10.1515/znb-2006-0617.

Full text

Abstract:

[{Hg(CF3)2}(ThpH)(H2O)](H2O) (1), [{Hg4(Thp)4}(ClO4)4(H2O)8](H2O)4 (2), [{Hg(ThpH)2} (NO3)](NO3) (3) and {Hg(Thp)Cl}(H2O) (4) (ThpH = theophylline, C7H8N4O2) have been synthesized by slow evaporation of aqueous solutions of the mercuric salts Hg(CF3)2, Hg(ClO4)2, Hg(NO3)2, or HgCl2 and theophylline. Their crystal structures were determined on the basis of single crystal X-ray data. The coordination polymers 1 and 2 crystallize with triclinic symmetry, P1̅ (no. 2), with a = 468.8(2), b = 1256.4(5), c = 1445.5(6) pm, α = 67.15(3), β = 89.21(3), γ = 89.40(3)° and a = 833.6(1), b = 1862.7(2), c = 2182.9(2) pm, α = 111.61(1), β = 90.98(1), γ = 95.51(1)°, respectively. 3 and 4 crystallize with monoclinic symmetry, Pc (no. 7), a =1194.1(1), b=1258.8(2), c=735.5(2) pm, β =96.96(2)° and P21/n (no. 14), a=1069.0(2), b =911.6(1), c=1089.9(2) pm and β = 96.87(2)°. In 1 the theophylline molecules are non-coordinating to mercury and leave the Hg(CF3)2 molecule unchanged. Only weak electrostatic attractions to one keto-oxygen atom of theophylline and one water molecule hold this co-crystallisate together. In 2, the theophyllinate anion, Thp−, strongly coordinates with both N(7) and N(9) to HgII forming a large ring with eight Hg atoms that incorporates the water molecules. One sort of nitrate ions in 3 is weakly attached to HgII with the theophylline molecules still bound strongly through N(9). The chloride ligand and the theophyllinate ion seem to have the same strengths as ligands in 4 as they are both attached to HgII with the shortest distances possible

APA, Harvard, Vancouver, ISO, and other styles

7

Wang, L. C., S. F. Man, and A. N. Belcastro. "Metabolic and hormonal responses in theophylline-increased cold resistance in males." Journal of Applied Physiology 63, no. 2 (August 1, 1987): 589–96. http://dx.doi.org/10.1152/jappl.1987.63.2.589.

Full text

Abstract:

The effects of theophylline (a phosphodiesterase inhibitor-adenosine receptor antagonist) and substrate feeding (Ensure, 250 kcal/235 ml) on cold resistance were studied in seminude males undertaking submaximal (50% maximum O2 consumption), intermittent (34% of total time) exercise in the cold (-5 to 15 degrees C, individually adjusted) for 3 h. Each subject (n = 7) served as his own control and was tested on a weekly schedule. Under control treatment, rectal temperature (Tre) decreased by 0.9 degrees C to approximately 36.2 degrees C after cold exposure, whereas under theophylline and Ensure, the decrease of Tre was only 0.4 degrees C, indicating a significant increase (P less than 0.05) in cold resistance (50% better than control). The plasma concentration of theophylline was 4.8–5.9 micrograms/ml and was positively correlated with plasma concentration of free fatty acids. Plasma norepinephrine (NE) increased significantly during cold exposure; the absolute concentration was significantly higher after theophylline pretreatment. The plasma concentrations of glucose, epinephrine, cortisol, and adenosine 3′,5′-cyclic monophosphate did not change and the changes of free thyroxine and triiodothyronine were minor. Together, the effectiveness of theophylline + Ensure in acutely increasing cold resistance may be due to increased substrate availability for thermogenesis, part of which, through theophylline's potentiation of both sympathetic release of NE and NE-stimulated lipolysis and part of which, through supplementary feeding of Ensure.

APA, Harvard, Vancouver, ISO, and other styles

8

Jeong, Chan Su, Soon Chul Hwang, Daniel W. Jones, Hwan Sun Ryu, Kieho Sohn, and Charles D. Sands. "Theophylline Disposition in Korean Patients with Congestive Heart Failure." Annals of Pharmacotherapy 28, no. 3 (March 1994): 396–401. http://dx.doi.org/10.1177/106002809402800319.

Full text

Abstract:

OBJECTIVE: This study proposed to determine the systemic disposition on of theophyllinein Korean adult patients during decompensated congestive heart failure compared with disposition after recovery. DESIGN: An experimental, prospective, self-controlled, non randomized design was used. SETTING: The study was performed in a general communityhospital located in Pusan, Korea. PATIENTS: Eight nonsmoking elderly Korean patients with decompensated congestive heart failure presenting to the emergency department were included in the study. Consecutive patients who met entrance criteria were selected. All patients completed the study. INTERVENTIONS: A single dose of aminophylline 6 mg/kg was administered by intravenous infusion over 30 minutes. Standard methods of congestive heart failure therapy were used in each patient, including bed rest, restriction of sodium, and drug therapy including digoxin. After compensation of congestive heart failure was achieved the theophylline infusion was repeated. OUTCOME MEASURES: Serum theophylline concentrations were measured at 2, 6, 12, and 18 hours after completion of the dose at base line and following treatment. RESULTS: A clinically and statistically significant improvement in mean theophylline total body clearance was demonstrated following treatment (from 21.7 ± 2.8 to 43.4 ± 4.7 mL/kg/h [mean ± SEM]; p<0.01). Comparison of these results with a computer model based on literature averages of peoples of all nationalities showed significant underprediction of theophylline clearance both before (p<0.05)and after (p<0.01) treatment. The theophylline elimination half-life prior to treatment was 18.2 ± 2.2 hours and decreased to 9.1 ± 0.8 hours following treatment(p<0.O1). There was no statistical difference between the computer-model predicted initial theophylline half-life and the measured value, but the model significantly underpredicted the improvement following treatment. CONCLUSIONS: The improvement in theophylline clearance demonstrated in this study appears to be greater than that reported for Western patients. This has practical application to the calculation of appropriate theophylline maintenance dosage regimens in Korean patients with cardiac failure. These data support the need for consideration of racial differences in individualizing dosage regimens. We suggest that all kinetic models, whether software supported or not, should consider incorporating ethnic origin as a demographic factor that helps select the proper model for individual patients.

APA, Harvard, Vancouver, ISO, and other styles

9

Rees, Sharon. "THEOPHYLLINE." Journal of Prescribing Practice 3, no. 2 (February 2, 2021): 52. http://dx.doi.org/10.12968/jprp.2021.3.2.52.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

&NA;. "Theophylline." Reactions Weekly &NA;, no. 728 (November 1998): 12. http://dx.doi.org/10.2165/00128415-199807280-00041.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

&NA;. "Theophylline." Reactions Weekly &NA;, no. 1167 (September 2007): 26. http://dx.doi.org/10.2165/00128415-200711670-00078.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

&NA;. "Theophylline." Reactions Weekly &NA;, no. 1152 (May 2007): 25–26. http://dx.doi.org/10.2165/00128415-200711520-00078.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

&NA;. "Theophylline." Reactions Weekly &NA;, no. 1371 (October 2011): 35–36. http://dx.doi.org/10.2165/00128415-201113710-00130.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

&NA;. "Theophylline." Reactions Weekly &NA;, no. 533 (January 1995): 11. http://dx.doi.org/10.2165/00128415-199505330-00042.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

&NA;. "Theophylline." Reactions Weekly &NA;, no. 544 (April 1995): 12. http://dx.doi.org/10.2165/00128415-199505440-00035.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Napier‐Flood, Fiona E., and Brian R. Creese. "Theophylline." Medical Journal of Australia 162, no. 10 (May 1995): 548–50. http://dx.doi.org/10.5694/j.1326-5377.1995.tb138519.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

&NA;. "Theophylline." Reactions Weekly &NA;, no. 433 (January 1993): 11. http://dx.doi.org/10.2165/00128415-199304330-00048.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

&NA;. "Theophylline." Reactions Weekly &NA;, no. 446 (April 1993): 12. http://dx.doi.org/10.2165/00128415-199304460-00053.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

&NA;. "Theophylline." Reactions Weekly &NA;, no. 452 (May 1993): 11. http://dx.doi.org/10.2165/00128415-199304520-00051.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

&NA;. "Theophylline." Reactions Weekly &NA;, no. 458 (July 1993): 11. http://dx.doi.org/10.2165/00128415-199304580-00057.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Barnes, Peter J. "Theophylline." Pharmaceuticals 3, no. 3 (March 18, 2010): 725–47. http://dx.doi.org/10.3390/ph3030725.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

&NA;. "Theophylline." Reactions Weekly &NA;, no. 621 (October 1996): 12. http://dx.doi.org/10.2165/00128415-199606210-00041.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

&NA;. "Theophylline." Reactions Weekly &NA;, no. 627 (November 1996): 12. http://dx.doi.org/10.2165/00128415-199606270-00036.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Weinberger, Miles M. "Theophylline." Immunology and Allergy Clinics of North America 10, no. 3 (August 1990): 559–76. http://dx.doi.org/10.1016/s0889-8561(22)00295-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Milgrom, Henry. "THEOPHYLLINE." Immunology and Allergy Clinics of North America 13, no. 4 (November 1993): 819–38. http://dx.doi.org/10.1016/s0889-8561(22)00662-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

&NA;. "Theophylline." Reactions Weekly &NA;, no. 791 (March 2000): 12. http://dx.doi.org/10.2165/00128415-200007910-00029.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

&NA;. "Theophylline." Reactions Weekly &NA;, no. 369 (September 1991): 11. http://dx.doi.org/10.2165/00128415-199103690-00060.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

&NA;. "Theophylline." Reactions Weekly &NA;, no. 371 (October 1991): 12. http://dx.doi.org/10.2165/00128415-199103710-00061.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

&NA;. "Theophylline." Reactions Weekly &NA;, no. 374 (October 1991): 8. http://dx.doi.org/10.2165/00128415-199103740-00042.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

&NA;. "Theophylline." Reactions Weekly &NA;, no. 380 (December 1991): 8. http://dx.doi.org/10.2165/00128415-199103800-00041.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

&NA;. "Theophylline." Reactions Weekly &NA;, no. 384 (January 1992): 12. http://dx.doi.org/10.2165/00128415-199203840-00065.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

&NA;. "Theophylline." Reactions Weekly &NA;, no. 403 (May 1992): 8. http://dx.doi.org/10.2165/00128415-199204030-00034.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

&NA;. "Theophylline." Reactions Weekly &NA;, no. 1199 (April 2008): 44. http://dx.doi.org/10.2165/00128415-200811990-00134.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

&NA;. "Theophylline." Reactions Weekly &NA;, no. 1214 (August 2008): 29. http://dx.doi.org/10.2165/00128415-200812140-00084.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Markham, Anthony, and Diana Faulds. "Theophylline." Drugs 56, no. 6 (1998): 1081–91. http://dx.doi.org/10.2165/00003495-199856060-00018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

&NA;. "Theophylline." Reactions Weekly &NA;, no. 915 (August 2002): 12. http://dx.doi.org/10.2165/00128415-200209150-00040.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

&NA;. "Theophylline." Reactions Weekly &NA;, no. 296 (April 1990): 7. http://dx.doi.org/10.2165/00128415-199002960-00032.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

&NA;. "Theophylline." Reactions Weekly &NA;, no. 307 (June 1990): 7. http://dx.doi.org/10.2165/00128415-199003070-00034.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

&NA;. "Theophylline." Reactions Weekly &NA;, no. 313 (August 1990): 8. http://dx.doi.org/10.2165/00128415-199003130-00042.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

&NA;. "Theophylline." Reactions Weekly &NA;, no. 328 (November 1990): 11. http://dx.doi.org/10.2165/00128415-199003280-00059.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

&NA;. "Theophylline." Reactions Weekly &NA;, no. 341 (March 1991): 11. http://dx.doi.org/10.2165/00128415-199103410-00067.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

&NA;. "Theophylline." Reactions Weekly &NA;, no. 347 (April 1991): 7. http://dx.doi.org/10.2165/00128415-199103470-00033.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

&NA;. "Theophylline." Reactions Weekly &NA;, no. 356 (June 1991): 8. http://dx.doi.org/10.2165/00128415-199103560-00037.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

&NA;. "Theophylline." Reactions Weekly &NA;, no. 359 (July 1991): 8. http://dx.doi.org/10.2165/00128415-199103590-00042.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

&NA;. "Theophylline." Reactions Weekly &NA;, no. 364 (August 1991): 12. http://dx.doi.org/10.2165/00128415-199103640-00058.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Nasser, Shuaib S. M., and P. John Rees. "Theophylline." Drug Safety 8, no. 1 (January 1993): 12–18. http://dx.doi.org/10.2165/00002018-199308010-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

&NA;. "Theophylline." Reactions Weekly &NA;, no. 506 (June 1994): 12. http://dx.doi.org/10.2165/00128415-199405060-00063.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

&NA;. "Theophylline." Reactions Weekly &NA;, no. 510 (July 1994): 12. http://dx.doi.org/10.2165/00128415-199405100-00056.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

&NA;. "Theophylline." Reactions Weekly &NA;, no. 1334 (January 2011): 43. http://dx.doi.org/10.2165/00128415-201113340-00153.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Svedmyr, Nils. "Theophylline." American Review of Respiratory Disease 136, no. 4_pt_2 (October 1987): S68—S71. http://dx.doi.org/10.1164/ajrccm/136.4_pt_2.s68.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!